First-Line Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
For typical CIDP, start with either intravenous immunoglobulin (IVIg) or corticosteroids as first-line treatment; both are equally effective and the choice depends primarily on patient comorbidities and preference. 1
Treatment Algorithm
Initial Treatment Selection
The 2021 European Academy of Neurology/Peripheral Nerve Society guideline establishes three first-line options 1:
- IVIg (strongly recommended)
- Corticosteroids (strongly recommended)
- Plasma exchange (reserved for cases where IVIg and corticosteroids fail)
For motor-predominant CIDP specifically, prioritize IVIg as the first choice over corticosteroids, as this variant tends to respond better to immunoglobulin therapy 1.
Practical Decision-Making
Choose IVIg when:
- Patient has diabetes, osteoporosis, or obesity (corticosteroid contraindications)
- Motor-predominant variant is present
- Rapid improvement is desired with fewer systemic side effects
Choose corticosteroids when:
- Cost is a limiting factor (significantly less expensive)
- IVIg availability is limited
- Patient can tolerate steroid side effects
Treatment Response Timeline
Evaluate response at 4 weeks after initiating therapy 2, 3. Approximately 40% of patients do not improve within the first 4 weeks, but this does not necessarily indicate treatment failure—progression may have been worse without therapy 4.
If insufficient response at 4 weeks: Switch to the alternative first-line agent (IVIg ↔ corticosteroids) or advance to plasma exchange 1.
Maintenance Therapy
Once initial response is achieved, transition to maintenance treatment with 1:
- IVIg (intravenous or subcutaneous formulations)
- Corticosteroids (continued)
- Consider combination therapy if high doses of either agent are required
Second-Line Considerations
If first-line therapies fail or require unacceptably high maintenance doses 1:
- Add immunosuppressants (azathioprine, mycophenolate, methotrexate)
- Consider rituximab for antibody-mediated subtypes
- Efgartigimod alfa (FcRn antagonist) is now FDA-approved for refractory CIDP, showing 61% reduction in relapses 2, 5
Critical Caveats
Treatment-related fluctuations (TRFs) occur in 6-10% of patients—defined as clinical worsening within 2 months after initial improvement 4. These indicate the inflammatory process is ongoing despite initial response. Repeat the full treatment course when TRFs occur.
Reconsider the diagnosis if there is complete lack of response to both IVIg and corticosteroids 6. CIDP is frequently misdiagnosed, and treatment failure should prompt diagnostic reassessment.
Distinguish CIDP from acute-onset CIDP: If patients experience three or more TRFs or deterioration ≥8 weeks after onset, the diagnosis shifts to acute-onset CIDP, which requires different long-term management 4.